Internal Market, Industry, Entrepreneurship and SMEs

Fifth stakeholder conference on biosimilar medicines

Fifth stakeholder conference on biosimilar medicines
Published on: 31/10/2019
On 30 October, the European Commission organised a multi-stakeholder conference in Brussels dedicated to biosimilar medicinal products. The meeting was organised in collaboration with the European Medicines Agency (EMA).
Event date: 30/10/2019

A wide variety of participants representing patients, healthcare professionals, authorities and pharmaceutical industry companies shared experiences on the use of biological medicines, including biosimilars. The discussions focused on policy choices and practices related to the uptake of biosimilars, in particular on the long-term sustainability of the biosimilar market.

As in previous years, IQVIA (formerly Quintiles & IMS Health) presented the updated 2019 report on the impact of biosimilar competition.

The 'information guide for healthcare professionals', previously available only in 8 EU languages, is now available in all 23 EU languages: EN, DE, FR, ES, IT, NL, PL, PT, BG, CZ, EL, DA, ET, FI, HR, HU, LT, LV, MT, RO ,SK, SL, SE.

The EMA prepared this guide in collaboration with the Commission and scientific experts from the EU countries. EU organisations representing doctors, nurses, pharmacists and patients also contributed to its development. The guide provides EU healthcare professionals with reference information on the science and regulation supporting the use of biosimilars.

Documents & links

Presentations

  1. Tools to optimise biosimilars benefits from a societal perspective - HU Semmelweis University
  2. A snapshot of the biosimilar market dynamics: IQVIA report 2019
  3. Market dynamics - a perspective from the Directorate-General for Competition
  4. Update on biosimilars in Germany - A German Physicians Association (KVWL) perspective
  5. Biosimilars in Slovakia - A Slovakian Union Health Insurance Fund perspective
  6. Promoting the use of biosimilars in France - A French Ministry of Solidarity & Health perspective
  7. Sustainable procurement of medicines - A perspective from the Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs
  8. How to improve early access to biosimilars - A pharmacist's perspective
  9. Biosimilars in the EU: A paradigm in regulatory science - A European Medicines Agency perspective
  10. How to improve early access to biosimilars - A patients organisation perspective
  11. Ways to foster biosimilars access to patients - A clinician perspective
  12. How to improve early access to biosimilars - A European specialist nurses organisation perspective
  13. Danish experience with biosimilars - A Danish Medicines Agency perspective
  14. Biosimilars in Hungary - A Hungarian Institute of Health Insurance Fund perspective

More information

Contact

Unit D3 - Biotechnology and Food Supply Chain GROW-D3@ec.europa.eu